SILVER SPRING
Olumiant cleared for severe alopecia areata in patients 12 and older
- Sponsor
- Eli Lilly and Company $LLY
- Drug
- Olumiant · baricitinib
- Indication
- Severe alopecia areata in pediatric patients 12 years and older
FDA approved Olumiant (baricitinib) for pediatric patients 12 years and older with severe alopecia areata, expanding the JAK inhibitor's US label.
Read original at prnewswire.com ↗Drug Watch — recent news on Olumiant
- Stopping baricitinib undoes T1D gains, Aus trial finds - the limbic
- Baricitinib Shows Durable Responses in Refractory cGVHD - Targeted Oncology
- The Treatment Stopped—Did the Benefit Last? New Baricitinib Data in Type 1 Diabetes - Diabetes In Control
- Baricitinib For Remission Induction And Glucocorticoid Sparing In New-Onset PMR Cracked Windshield Southwest Airlines Flight (lLQ1hPRdKM) - Mshale
- Providence Swedish enrolling patients in Long COVID clinical trial - The Daily Chronicle
Sponsor Watch — recent news on Eli Lilly and Company
- Eli Lilly (LLY) Stock Fair Value Edges Higher As Analysts Back GLP 1 Growth
- A drugmaker is gaining from the side effects of weight-loss drugs
- Pfizer to Share Revenue With HHS in Deal on Overseas Drug Prices
- How to position for the next wave of AI-led scientific breakthroughs
- What About the Energy Sector?